Valeant CEO to Give Deposition to Senate, Avoiding Contempt
- Pearson to appear for deposition with committee on April 18
- Panel says it will postpone vote to hold Pearson in contempt
Valeant Gets Default Notice From Creditors
This article is for subscribers only.
Mike Pearson, chief executive officer of Valeant Pharmaceuticals International Inc., will comply with a congressional subpoena and give a deposition to a Senate committee investigating drug pricing, reversing course after previously saying he would not do so.
Pearson will give his deposition to the Senate Special Committee on Aging on April 18, ahead of an April 27 hearing in Washington where he was already scheduled to testify, the committee said in a statement Wednesday. As a result, the panel said it has postponed a vote to hold Pearson in contempt of Congress. Congressional committees often gather documents or meet privately with witnesses ahead of public hearings.